ALK-ABELLÓ A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 150.9 DKK | -4.85% |
|
+3.50% | +49.11% |
| 06-21 | ALK-Abelló A/S Updates Revenue Guidance for the Year 2024 | CI |
| 06-21 | ALK Provides Update on Regulatory Process for the House dust Mite Allergy Tablet in China | CI |
Presenter SpeechPer Plotnikof (Executives)Ladies and gentlemen, welcome to ALK's Capital Marke...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
ALK-Abello A/S is a Denmark-based company active within the pharmaceutical industry. It is engaged in the development and marketing of pharmaceutical products for the treatment, prevention and diagnosis of allergy. Its product portfolio comprises allergy vaccines, emergency treatments and allergy diagnostics products. The Companyâs allergy vaccines product offering comprises tablet vaccines, sublingual vaccines and subcutaneous vaccines. Its emergency treatments product offering comprises products for the management of anaphylaxis. Its allergy diagnostics product offering comprises allergen extracts for allergy testing, such as skin-prick tests. The Company operates worldwide through subsidiaries, production units and distributors in such countries as Austria, Canada, France, Italy, the Netherlands, Poland, Spain, Switzerland, the United States and China.
Sector
Pharmaceuticals
Calendar
22/08/2024
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
158.6
DKK
Average target price
155.4
DKK
Spread / Average Target
-2.02%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +49.11% | 5.03B | |
| +55.28% | 815B | |
| +44.25% | 654B | |
| -6.35% | 354B | |
| +22.06% | 337B | |
| +10.85% | 302B | |
| +18.45% | 247B | |
| +2.09% | 229B | |
| +13.03% | 219B | |
| +9.56% | 171B |
- Stock Market
- Equities
- ALK B Stock
- News ALK-Abelló A/S
- Transcript : ALK-Abelló A/S - Analyst/Investor Day
